# US 11,898,156 B2 · Nano-vesicles derived from genus Morganella bacteria and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,898,156 B2
- Document ID: US11898156B2
- Status: Granted
- Kind: B2
- Application number: 17/082,008
- Filed: 2020-10-28
- Published: 2021-02-25
- Granted: 2024-02-13
- Earliest claimed: 2018-01-12
- Assignees: Md Healthcare Inc.
- Applicants: Md Healthcare Inc.
- Inventors: Yoon-Keun Kim
- Web page: https://patentgrep.com/patent/US11898156B2

## CPC

- C12N 15/88: using microencapsulation, e.g. using {amphiphile} liposome vesicle
- A23L 33/10: using additives (addition of substantially indigestible substances A23L33/21)
- A61K 9/1271: Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers (liposomes as conjugates {A61K47/6911})
- A61K 35/74: Bacteria (therapeutic use of a bacterial protein A61K38/00)
- A61P 35/00: Antineoplastic agents
- C12N 1/20: Bacteria; Culture media therefor
- C12N 1/205: Bacterial isolates
- C12Q 1/06: Quantitative determination
- C12Q 1/686: Polymerase chain reaction [PCR]
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- C12Q 1/689: for bacteria
- C12R 2001/01: Bacteria or Actinomycetales {; using bacteria or Actinomycetales}
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12R: INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention relates to vesicles derived from genus Morganella bacteria and a use thereof, the present inventors experimentally confirmed that the vesicles were significantly decreased in clinical samples derived from patients with a malignant disease such as gastric cancer, colorectal cancer, pancreatic cancer, bile duct cancer, breast cancer, ovarian cancer, bladder cancer, prostate cancer and lymphoma, a cardiovascular disease such as myocardial infarction, cardiomyopathy, atrial fibrillation, variant angina, and stroke, diabetes mellitus, and Parkinson's disease as compared to normal persons, and the vesicles suppressed the secretion of inflammatory mediators by pathogenic vesicles and suppressed the occurrence of cancer, so that the vesicles derived from genus Morganella bacteria may be usefully used for the purpose of developing a method for diagnosing a malignant disease such as gastric cancer, colorectal cancer, pancreatic cancer, bile duct cancer, breast cancer, ovarian cancer, bladder cancer, prostate cancer and lymphoma, a cardiovascular disease such as myocardial infarction, cardiomyopathy, atrial fibrillation, variant angina, and stroke, diabetes mellitus, and Parkinson's disease, and a composition for preventing or treating the diseases or an inflammatory disease.

## Claims

### Claim 1

A method of reducing inflammation mediated by TNF-α or IL-6, the method comprising administering to a subject in need thereof a composition comprising an effective amount of vesicles derived from bacteria belonging to Morganella morganii, and thereby reducing inflammation mediated by TNF-α or IL-6, wherein the composition does not contain the cells of Morganella morganii.

### Claim 2 (depends on 1)

The method of claim 1, wherein the composition is a pharmaceutical composition or a food composition.

### Claim 3 (depends on 1)

The method of claim 1, wherein the vesicles have an average diameter of 10 to 200 nm.

### Claim 4 (depends on 1)

The method of claim 1, wherein the vesicles are naturally or artificially secreted from the bacteria belonging to Morganella morganii.

### Claim 5 (depends on 1)

The method of claim 1, wherein the composition is an inhalant composition.

### Claim 6 (depends on 1)

The method of claim 1, wherein the composition is administered orally or by injection.

### Claim 7 (depends on 1)

The method of claim 1, wherein the composition is administered in combination with other therapeutic agents.

### Claim 8 (depends on 7)

The method of claim 7, wherein the composition and other therapeutic agents are administered sequentially or simultaneously.

### Claim 9 (depends on 1)

The method of claim 1, wherein the composition is administered daily or every other day.